Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Developer: Eli Lilly and Company | Administration in Trials: Once-weekly subcutaneous injection First successful Phase 3 trial (TRIUMPH-4, topline Dec 2025): Up to 28.7% average body weight loss at 68 weeks (highest dose) in adults with obesity/overweight and knee osteoarthritis
Prevention of secondary caries using silver diamine fluoride treatment and casein phosphopeptide-amorphous calcium phosphate modified glass-ionomer cement
GEHA-covered dietitians also guide clients seeking preventive support, weight management, sports performance improvement, intuitive eating, or better energy levels
However, the severity may differ
US$ 20.52
US$ 21.97
US$ 23.11
US$ 21.41
